id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1802283,d92ed2b6-aa21-4fe6-9ede-9f216a7226cb,1T,"BOCKORNY GROUP, INC.",289773,GENERIC PHARMACEUTICAL ASSOCIATION,2016,first_quarter,PHA,"Issues Related to Biosimilar Regulation, Labeling, E-Labeling and Access","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,1,2016-02-02T11:59:12.727000-05:00
1802389,cfef6b65-cc4f-4545-85e9-2f881199e3c9,1T,MARTA AGUIRRE BASCOM,307411,THE NATIONAL RETIREE LEGISLATIVE NETWORK,2016,first_quarter,PHA,Support for importation of prescription drugs from Canada; competitive bidding for pharmaceuticals through Medicare.,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,1,2016-03-21T13:46:16.893000-04:00
1803011,c0ce498c-c145-49e2-af0d-f83223f4fbf1,Q1,NELSON MULLINS RILEY & SCARBOROUGH,285871,"INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.)",2016,first_quarter,PHA,Any legislation and regulation to the treatment of opioid abuse.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-04-05T11:02:35.047000-04:00
1804461,49d733ec-7535-45fd-bd93-fa6dace6cd3e,Q1,"NAHIGIAN STRATEGIES, LLC",322897,TEVA PHARMACEUTICALS USA INC,2016,first_quarter,PHA,Advocate for pathway to improving existing therapies.,,45000,,0,0,2016-04-11T09:56:06.933000-04:00
1804653,ee8d3055-d501-4081-990e-55e3053ee944,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,ROCK & ASSOCIATES,2016,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",18000,,0,0,2016-04-11T12:05:13.997000-04:00
1804761,d3279a37-3222-4a09-b721-72ab7760d58f,Q1,KATE MOSS,25988,CVS HEALTH,2016,first_quarter,PHA,Issues related to prescription drug abuse and drug supply chain safety.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2016-04-11T14:22:54.557000-04:00
1804908,cb3c5a80-0ec3-4529-bbf5-f5bd48a12ba5,Q1,"CARD & ASSOCIATES, LLC",84217,AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY),2016,first_quarter,PHA,Educate Members on pharmacy contracting with pharmacy benefit managers,"HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2016-04-11T16:05:11.117000-04:00
1804909,76f175ff-9604-4c6f-ae57-8a4569d1d75c,Q1,"CARD & ASSOCIATES, LLC",84217,CLOAKROOM ADVISORS LLC ON BEHALF OF LINDEN CARE LLC,2016,first_quarter,PHA,Educate Members on pharmacy contracting with pharmacy benefit managers,"HOUSE OF REPRESENTATIVES,SENATE",22500,,0,0,2016-04-11T16:07:13.117000-04:00
1804961,2973adf9-03ff-4f09-990b-7443156efe34,Q1,DENTONS US LLP,36105,PHRMA,2016,first_quarter,PHA,HR 9 and other legislation regarding patent law reform and treatment of pharmeceuticals,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-04-11T17:03:18.047000-04:00
1804969,3e2b14e5-6f44-4795-b35f-68cb8a33600b,Q1,"TCH GROUP, LLC",51478,"CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION)",2016,first_quarter,PHA,"S.483, Ensuring Patient Access and Effective Drug Enforcement Act of 2015",SENATE,20000,,0,0,2016-04-11T17:35:31.027000-04:00
1805129,1311acbd-1a38-4f21-8e6c-e8003028555a,1T,"CHRISTY ELLERBEE CONSULTING, LLC",401103332,"INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.)",2016,first_quarter,PHA,"H.R. 2872 Opioid Addiction Treatment Modernization Act.
H.R. 1821 and S. 707 Opioid Overdose Reduction Act of 2015.
H.R. 2536 and S. 1455 TREAT ACT.","HOUSE OF REPRESENTATIVES,SENATE",,,0,1,2016-04-12T10:19:29.280000-04:00
1805311,3a518805-40f8-4a60-a5b8-d1a748006883,Q1,WAXMAN STRATEGIES,401103693,340B HEALTH,2016,first_quarter,PHA,Laws and regulations affecting the 340B Drug Discount Program,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES",18750,,0,0,2016-04-12T12:35:13.297000-04:00
1805341,2de2906e-1bd6-4ebf-8530-1097b76e5b99,Q1,NELSON MULLINS RILEY & SCARBOROUGH,285871,CASCADE HEMOPHILIA CONSORTIUM,2016,first_quarter,PHA,Issues related to 340B Drug Pricing Progam,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-04-12T13:12:11.533000-04:00
1805344,7f17808f-9a88-4b53-bdf8-5ae5ad891b25,Q1,NELSON MULLINS RILEY & SCARBOROUGH,285871,HEMOPHILIA OF GEORGIA,2016,first_quarter,PHA,"Issues related to implementation of the ACA, Hemophilia research and treatments, and the 340B Drug Pricing Program","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2016-04-12T13:13:13.347000-04:00
1805402,56e74afd-3300-48a3-9a0c-0413f3586af5,Q1,HOLLAND & KNIGHT LLP,18466,THE BIOSIMILARS FORUM,2016,first_quarter,PHA,"Medicare reimbursement issues, FDA regulation of biosimilars.","HOUSE OF REPRESENTATIVES,SENATE",120000,,0,0,2016-04-12T14:08:24.290000-04:00
1805404,03f25f92-793d-4b4b-b7e4-aa101dedae3a,Q1,HOLLAND & KNIGHT LLP,18466,PROTECTING ACCESS TO PAIN RELIEF COALITION,2016,first_quarter,PHA,Advocating for policy to ensure patient access to pain relief.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2016-04-12T14:09:26.243000-04:00
1805448,7b1d53cc-c55f-404d-a9a8-4bf89d156f00,Q1,ROCK & ASSOCIATES,33545,"BRAIDWOOD MANAGEMENT, INC.",2016,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-04-12T14:26:04.387000-04:00
1805457,1a4dbf74-eab7-459c-96fb-8579dd9ada8e,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,THE HEMOPHILIA ALLIANCE,2016,first_quarter,PHA,issues related to the 340B drug discount program,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-04-12T14:29:15.183000-04:00
1805463,c4e7f82d-452c-470e-baf2-3d90df3c7fe9,Q1,ROCK & ASSOCIATES,33545,DIAMONDBACK DRUGS,2016,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-04-12T14:31:22.933000-04:00
1805472,f7114d59-50f2-4944-9514-9513a08d08c3,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,AMERICAN SOCIETY OF HEMATOLOGY,2016,first_quarter,PHA,"HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2016-04-12T14:34:31.667000-04:00
1805481,0d8b4b36-c121-49f9-a273-560f782f738b,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL ASSOCIATION OF EPILEPSY CENTERS,2016,first_quarter,PHA,Issues related to anti-epileptic drugs.,"Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,0,2016-04-12T14:36:34.793000-04:00
1805488,17e76074-b95c-4e90-8b7a-911643488192,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL HEMOPHILIA FOUNDATION,2016,first_quarter,PHA,"Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program.
HR 1600, Patients Access to Treatment Act","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE",50000,,0,0,2016-04-12T14:38:38.027000-04:00
1805508,b18b7eff-1c16-44c6-b968-9677553c4e05,Q1,ROCK & ASSOCIATES,33545,"VETERINARY PHARMACIES OF AMERICA, INC.",2016,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-04-12T14:49:00.547000-04:00
1805516,b305fa16-79a1-4f4d-a0bc-92cce935e52e,Q1,ROCK & ASSOCIATES,33545,"WEDGEWOOD VILLAGE PHARMACY, INC.",2016,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-04-12T14:52:11.593000-04:00
1805521,ad13df8b-2477-4000-ad66-456acdc487d6,Q1,ROCK & ASSOCIATES,33545,WOMEN'S INTERNATIONAL PHARMACY,2016,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-04-12T14:54:19.407000-04:00
1805535,363c7b0d-83ff-4354-8473-19e03bcd716e,Q1,ROCK & ASSOCIATES,33545,TOWN & COUNTRY COMPOUNDING AND CONSULTING,2016,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2016-04-12T14:59:36.093000-04:00
1805543,4d8f72b1-68ba-4b8d-a62b-bb6f6b22d563,Q1,ROCK & ASSOCIATES,33545,WELLNESS PHARMACY,2016,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2016-04-12T15:04:46.640000-04:00
1805603,906a2a8d-25e3-4545-afd0-e2b75957bd59,Q1,"PRINTING INDUSTRIES OF AMERICA, INC.",32203,PRINTING INDUSTRIES OF AMERICA INC,2016,first_quarter,PHA,Pharmaceutical Printed Literature,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Labor Relations Board (NLRB),Occupational Safety & Health Administration (OSHA),Securities & Exchange Commission (SEC),SENATE,U.S. Postal Service (USPS)",,100000,0,0,2016-04-12T15:28:50.723000-04:00
1806070,6ad7a8f1-b687-4c1d-8a08-961e9cb2cb8a,Q1,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2016,first_quarter,PHA,Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,128875,0,0,2016-04-13T11:24:52.810000-04:00
1807311,16d4a9e2-91fd-48d3-9733-ab52eeb11cdf,Q1,MASSACHUSETTS MEDICAL SOCIETY,23975,MASSACHUSETTS MEDICAL SOCIETY,2016,first_quarter,PHA,"S 320 - Medical Innovation Act  - NIH funding  

DEA - change/classification of regulations regarding partial fill of prescriptions

Prescription Drug Pricing - no specific bill
Direct to Consumer Advertising - no specific bill
Negotiating Prescription Drug Prices for Medicare and Medicaid - no specific bill","Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,State, Dept of (DOS)",,90000,0,0,2016-04-14T11:16:15.737000-04:00
1807383,4c456778-f1d2-4b37-a365-7b98c26fda99,Q1,BROWN RUDNICK LLP,287895,HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC,2016,first_quarter,PHA,H.R. 471 & S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 524 relating to the prevention and treatment of opioid addiction,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-04-14T11:58:17.257000-04:00
1807389,ba39d598-cee3-4a85-ba88-7a6a0e55a008,Q1,BROWN RUDNICK LLP,287895,PRIME THERAPEUTICS,2016,first_quarter,PHA,"HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244, the MAC Transparency Act","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-04-14T12:02:31.053000-04:00
1807391,61e9a3cb-d116-4941-8bd8-0aeef0d7e09f,Q1,BROWN RUDNICK LLP,287895,AMNEAL PHARMACEUTICALS,2016,first_quarter,PHA,Federal policy relating to abuse deterrent drug development,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2016-04-14T12:04:32.757000-04:00
1807392,7c8566cb-ac6e-4fe6-a8d8-eca91a26449a,Q1,BROWN RUDNICK LLP,287895,"EXELA HOLDINGS, LLC",2016,first_quarter,PHA,Federal policy relating to pharmaceutical pricing and FDA application review protocols,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2016-04-14T12:06:34.257000-04:00
1807402,3b99e3f7-f6f1-423b-948b-e263f0091c3f,Q1,BROWN RUDNICK LLP,287895,ZYDUS PHARMACEUTICALS USA INC.,2016,first_quarter,PHA,Federal policy relating to pharmaceutical pricing,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-04-14T12:07:41.273000-04:00
1807476,2582a572-f6cd-41ea-8e58-10433d1db351,Q1,RED+BLUE STRATEGIES,400693064,EXPRESS SCRIPTS INC.,2016,first_quarter,PHA,"National Defense Authorization Act of FY 2017 - Work to ensure that the current treatment of mail order for retired and active military personnel and their families remains constant in the pending Authorization bill. 

The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.  

The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders.  Particular focus on formulary policies. 

FDA's March 31, 2016 biosimilar labeling guidance and additional work regarding biosimilars. 

Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.

Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.

Issues related to mail order coverage for Medicare, Medicaid, Exchanges, Tricare and other programs.

Issues related to the pricing of prescription medications.

 

Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. 

Issues related to the treatment of pharmacy benefit managers in federal programs. 

Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. 

Issues related to access and affordability for prescription medications for both government and private sector benefit programs.

H.R. 1735 - National Defense Authorization Act for Fiscal Year 2016 - issues related to prescription drug coverage options for retired and active military personnel.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-04-14T12:51:48.827000-04:00
1807530,bda1c18a-912d-49ac-9203-32a121bcc6e6,Q1,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2016,first_quarter,PHA,"The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.  

The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders.  Particular focus on formulary policies. 

FDA's March 31, 2016 biosimilar labeling guidance and additional work regarding biosimilars. 

Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.

Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.

Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.

CCIIO issuer letter and additional guidance and regulations focused on programs in the Exchanges that impact coverage and access to prescription medications and pharmacy networks. 

Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. 

Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. 

CMS call letter focused on changes in policies regarding mail order and pharmacy networks. 

Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.

CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks. 

Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. 

Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. 

CMS call letter focused on changes in policies regarding mail order and pharmacy networks. 

Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.


Issues related to patents and the treatment of prescription medications.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-04-14T13:15:39.937000-04:00
1807600,8bedf915-8aac-4f07-a722-1921d96026c7,Q1,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2016,first_quarter,PHA,"S. 524 - The Comprehensive Addiction and Recovery Act - supporting efforts to fight opioid abuse in the United States.  Work focused on the inclusion of ""lock in"" programs in the Medicare program to prevent and protect seniors from opioid addiction.  

S.185 - The Promise for Antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public.

S. 2153 - Provider Payment Sunshine Act - policies supporting the inclusion of all prescribers to the Open Payments program. 
 
Legislative and regulatory issues surrounding unique device identifiers (UDI) being addressed by CMS, FDA and ONC. 

Advancing provisions to highlight Antibiotic Innovation and combating prescription drug abuse in the President's FY 2017 budget. 

Supporting policies to maintain the integrity of laws regarding compounding of certain medications.

Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-04-14T13:41:12.660000-04:00
1807609,4c2c33b6-75db-4a28-aa02-c3c0113d4af8,Q1,SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,35968,SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,2016,first_quarter,PHA,Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding.,"Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE",,70000,0,0,2016-04-14T13:44:19.660000-04:00
1807895,587576ff-5a14-47ca-87f3-f458b728406b,Q1,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN),2016,first_quarter,PHA,"Policy matters related to generic pharmaceuticals and biosimilars including naming, labeling, access and interchangeability and changes to the Risk Evaluation and Mitigation Strategies (REMS) program, H.R.2841, FAST Generics Act of 2015.  Issues related to House Energy and Commerce Committee's draft on H. R. 6, 21st Century Cures Act and the Senate Health, Education, Labor and Pensions Committee Initiative for Healthier Americans.  Affordability and pricing of pharmaceuticals.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",60000,,0,0,2016-04-14T15:14:23.153000-04:00
1807936,1f75c68f-fcf1-40c9-a148-5d95408abf12,Q1,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,27478,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,2016,first_quarter,PHA,"H.R. 244 - MAC Transparency Act of 2015; 
Congressional Oversight of 340 B Program;
S. 1406 - Saving Access to Compounding Medications for Special Needs Patients Act;
Direct and Indirect Remuneration fees (DIR);
Issues related to FDA implementation of The Drug Quality and Security Act related to compounding","Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE",,410000,0,0,2016-04-14T15:38:17.923000-04:00
1807988,f8102a82-bec7-4ff1-bdd4-7e0107f33425,Q1,COREWELL HEALTH,298455,COREWELL HEALTH,2016,first_quarter,PHA,RIN-0906-AB08 - Health Resources and Services Administration; 340B Drug Pricing Program Omnibus Guidelines; Submitted comments.,"Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,24000,0,0,2016-04-14T16:00:21.177000-04:00
1808058,6af77c60-c1b8-4d63-a464-4e016b2ba46e,Q1,RED+BLUE STRATEGIES,400693064,BLUE CROSS BLUE SHIELD OF MASSACHUSETTS,2016,first_quarter,PHA,Issues related to stemming the opioid epidemic in America and solutions developed by BCBSMA to combat abuse.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-04-14T16:21:45.960000-04:00
1808094,9a5dd130-2e57-44c3-a99d-43de978a5cf9,Q1,APOTEX CORP.,310973,APOTEX CORP.,2016,first_quarter,PHA,"H.R. 2841, The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing;

S. 2615, the Increasing Competition in Pharmaceuticals Act, provisions relating to priority review vouchers for and expedited approval of certain generic drug applications, and Risk Evaluation and Mitigation (REMS) programs;

Federal policy relating to requirements for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals;

S. 131, The FAIR Generics Act, provisions relating to market blockages caused by ""parked"" 180 day exclusivity period;

Federal policy relating to the Implementation of Public Law 112-144, The Food and Drug Administration Safety and Innovation Act, Title 3, Fees Relating to Generic Drugs; and

Federal policy relating to generic drug prices.","HOUSE OF REPRESENTATIVES,SENATE",,130000,0,0,2016-04-14T16:41:20.290000-04:00
1808105,8043822d-89e5-40ae-a031-c2086577e96e,Q1,RED+BLUE STRATEGIES,400693064,COHERUS BIOSCIENCES,2016,first_quarter,PHA,"FDA's March 31, 2016 Biosimilars Labeling Guidance.

Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have on drug cost and access.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-04-14T16:42:24.337000-04:00
1808436,5cbe6bf3-f780-4c22-ba0c-f4bb0fd67117,Q1,ACADEMY OF MANAGED CARE PHARMACY,48793,ACADEMY OF MANAGED CARE PHARMACY,2016,first_quarter,PHA,"Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017.","Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,159000,0,0,2016-04-15T11:02:53.540000-04:00
1808606,810dbd18-6552-4419-bb94-1e4234abb58b,Q1,CAPITOL HILL CONSULTING GROUP,72053,PURDUE PHARMA LLP,2016,first_quarter,PHA,Controlled Drug Substances Act (21 USC 13),"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2016-04-15T12:00:03.030000-04:00
1808767,14f8ec1d-f540-432b-afb5-e736e62376b7,Q1,CAPITOL HILL CONSULTING GROUP,72053,ENDO PHARMACEUTICALS,2016,first_quarter,PHA,Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2016-04-15T13:11:20.730000-04:00
1808779,8c8474a4-b5ee-4c36-b45a-96c6bee6a528,Q1,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2016,first_quarter,PHA,"Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483, S. 524, H.R. 953); 21st Century Cures (H.R. 6); Importation of Prescription Drugs (S. 122, H.R. 2228)","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,314000,0,0,2016-04-15T13:15:31.480000-04:00
1809553,8090c317-6050-4132-a8a8-76ebbcb02aaf,Q1,ANIMAL HEALTH INSTITUTE,4037,ANIMAL HEALTH INSTITUTE,2016,first_quarter,PHA,Issues related to illegal drug manufacturing under the guise of pharmacy compounding; Issues related to the granting of Categorical Exclusions from Environmental Assessments for animal health products.,"HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2016-04-16T09:37:40.040000-04:00
1809623,1cba34c4-d17b-4bc3-b140-767e91523431,Q1,AMERICAN COLLEGE OF EMERGENCY PHYSICIANS,1967,AMERICAN COLLEGE OF EMERGENCY PHYSICIANS,2016,first_quarter,PHA,"H.R.2298-Medicare Patient Safety and Drug Abuse Prevention Act

S.1913-Stopping Medication Abuse and Protecting Seniors Act of 2015","HOUSE OF REPRESENTATIVES,SENATE",,661366,0,0,2016-04-16T17:06:51.847000-04:00
1809967,fb04bd9c-e3df-4f2b-a2ad-b740c2f5bb3f,Q1,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2016,first_quarter,PHA,Hospital discounts; 340B Program,"Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)",,1250000,0,0,2016-04-18T08:44:56.283000-04:00
1810102,8d033662-8c97-4e45-a113-f98267ac7906,Q1,"WILLIAMS AND JENSEN, PLLC",41454,FAGRON NORTH AMERICA,2016,first_quarter,PHA,Issues related to Drug Quality and Security Act (DQSA) and Pharmacy compounding.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2016-04-18T09:38:44.587000-04:00
1810293,80e67964-c405-4ea1-86dd-28c2dce95ba9,Q1,CLOAKROOM ADVISORS LLC,401103204,LINDEN CARE LLC,2016,first_quarter,PHA,Congressional delegation outreach and education on issues related to speciality pharmacies,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-04-18T10:42:24.063000-04:00
1810498,19d46aa8-c889-4285-b923-1d176dffb620,Q1,ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,58534,ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,2016,first_quarter,PHA,"Any language supporting the expanded use of virtual care/telemedicine, including HR 2799 supporting changes in definitions to expand the use of telemedicine.","HOUSE OF REPRESENTATIVES,SENATE",,54115,0,0,2016-04-18T11:46:20.873000-04:00
1810507,5fc053d9-04e3-4e97-960f-9244c032f558,Q1,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,31348,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,2016,first_quarter,PHA,"Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price.  Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and   medical loss ratio).

Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. 

Issues related to prescription drug abuse in Medicare.

H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of  Medicare data

H.R.244, The MAC Transparency Act

H.R.793S1190, The Ensuring Seniors Access to Local Pharmacies Act

H.R. 1021, The Protecting the Integrity of Medicare Act

H.R.1600, The Patient Access to Treatments Act

H.R. 804, The Access to Medicare Data Act

H.R. 2298, The Medicare Drug Abuse Prevention Act

H.R. 6, Century Cures Act","Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),General Services Administration (GSA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE",,696470,0,0,2016-04-18T11:47:35.420000-04:00
1810811,6417723f-06ac-45a7-a45c-5b85cc784d9e,1T,"RUBICON ADVISORS, LLC",315091,"CIPLA USA, INC.",2016,first_quarter,PHA,"Food and Drug Administration, Generic Drug User Fees","HOUSE OF REPRESENTATIVES,SENATE",45000,,0,1,2016-04-18T13:00:58.647000-04:00
1810872,a150b011-0910-4043-a912-19d9c4974c26,Q1,"POWERS PYLES SUTTER & VERVILLE, P.C.",32008,340B HEALTH,2016,first_quarter,PHA,"Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3) funding of the Health Resources and Services Administration (HRSA)under the Labor Health & Human Services & Education appropriations bills.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-04-18T13:20:03.853000-04:00
1811002,9383f4f3-1ec5-422d-b436-690f34ea36a1,Q1,"RUBICON ADVISORS, LLC",315091,TEVA PHARMACEUTICALS USA,2016,first_quarter,PHA,21st Century Cures Act,"HOUSE OF REPRESENTATIVES,SENATE",105000,,0,0,2016-04-18T13:57:10.480000-04:00
1811010,e2459f3b-f11b-4955-b562-1a60b478a3bd,Q1,"RUBICON ADVISORS, LLC",315091,OFFICE OF GOVERNOR NATHAN DEAL,2016,first_quarter,PHA,"Pharmaceuticals
HR 707, Restoration of America's Wire Act","HOUSE OF REPRESENTATIVES,SENATE",43750,,0,0,2016-04-18T13:59:13.933000-04:00
1811018,d2481333-7aef-4487-95aa-cd55039ad104,Q1,NOVO NORDISK INC.,284790,NOVO NORDISK INC.,2016,first_quarter,PHA,P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations,,,910000,0,0,2016-04-18T14:00:17.933000-04:00
1811029,3b61609e-6071-4941-989b-fdda67e88149,Q1,"RUBICON ADVISORS, LLC",315091,DYNAVAX TECHNOLOGIES,2016,first_quarter,PHA,Pharmaceuticals,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2016-04-18T14:05:36.793000-04:00
1811033,a0d66e1a-24c3-426e-973d-911e968082f4,Q1,"RUBICON ADVISORS, LLC",315091,ALLIANCE TO PREVENT THE ABUSE OF MEDICINES,2016,first_quarter,PHA,Prescription drug abuse policy,"HOUSE OF REPRESENTATIVES,SENATE",52500,,0,0,2016-04-18T14:06:40.420000-04:00
1811038,f32c1074-f07f-4b95-ae11-5d8a2ccfbf15,Q1,"RUBICON ADVISORS, LLC",315091,COLLEGE OF AMERICAN PATHOLOGISTS,2016,first_quarter,PHA,"Physician Payment Rates, Electronic Health Records Incentives program","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-04-18T14:08:46.843000-04:00
1811041,db6a4198-6c22-40b9-b2d4-3a8785afc0b6,Q1,"RUBICON ADVISORS, LLC",315091,"DR. REDDY'S LABORATORIES, LTD",2016,first_quarter,PHA,"Food and Drug Administration, Generic Drug User Fees","HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2016-04-18T14:09:52.827000-04:00
1811128,5752e426-29ac-4bc3-b4ab-03beb5b9f10f,Q1,"HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC",17966,ELI LILLY AND COMPANY,2016,first_quarter,PHA,Issues relating to prescription drug prices.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-04-18T14:23:55.797000-04:00
1811244,2ee935d5-034b-4463-bbe7-2d74b13d31d0,Q1,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2016,first_quarter,PHA,"General Pharmacy Issues; HR6, 21st Century Cures; opioid abuse; specialty drug pricing","Equal Employment Opportunity Commission (EEOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2016-04-18T14:47:23.690000-04:00
1811277,59ce7d76-0b14-44eb-a5c5-0a57e05b4e80,Q1,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2016,first_quarter,PHA,"Discussion with Congressional staff regarding the use of antimicrobials in food-producing animals, particularly with respect to H.R. 1552 (Preservation of Antibiotics for Medical Treatment Act
S.621 (Preventing Antibiotics Resistance Act), and FDA's strategy (GRI #209 and VFD Rule) 
Discussion with Congressional staff and FDA to express the need for compounding of medications for use in animals and FDA's draft GFI #230
Inquiries to and discussions with, Congressional staff on veterinary pet prescriptions, particularly regarding our opposition to H.R. 3174/S. 1200 - The Fairness to Pet Owners Act
Discussions with DEA regarding use of controlled substances by veterinary practitioners.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE",,200000,0,0,2016-04-18T14:53:51.690000-04:00
1811492,41e2a128-2b5c-48a9-b12d-60b2791a6762,Q1,"MERCURY PUBLIC AFFAIRS, LLC",70175,KALISPELL REGIONAL HEALTHCARE,2016,first_quarter,PHA,Veteran pharmacy issues and polices,"Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",30000,,0,0,2016-04-18T15:31:24.303000-04:00
1811516,1f54cde5-24e7-4433-9d6b-a727e5ce3e7a,Q1,EMPIRE CONSULTING GROUP,400703105,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2016,first_quarter,PHA,Issues relating to Medicare Parts D and D; prescription drug costs/pricing;and 340 B drug pricing program.,HOUSE OF REPRESENTATIVES,40000,,0,0,2016-04-18T15:38:56.430000-04:00
1811593,efae68cb-98f6-49cf-870e-ccae923a5dfb,Q1,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",4653,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",2016,first_quarter,PHA,"Proposals relating to the regulation of direct to consumer prescription drug advertising 
H.R. 4565, Responsibility in Drug Advertising Act of 2016, to prohibit for three years after FDA approval direct to consumer prescription drug advertising","Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE",,460000,0,0,2016-04-18T15:48:18.870000-04:00
1811900,dfb9881d-421e-437d-9893-0aad7cc76cad,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,CHILDREN'S NATIONAL MEDICAL CENTER,2016,first_quarter,PHA,"Representation on health-related issues including reimbursement, research, public-health & clinical care","Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2016-04-18T16:40:37.187000-04:00
1812189,e7e1b47f-1908-4be4-a1e4-f426cc811c4f,Q1,"HIGHMARK, INC.",18238,HIGHMARK INC,2016,first_quarter,PHA,Opioid Abuse; Prescription Drugs; Specialty Drugs,"HOUSE OF REPRESENTATIVES,SENATE",,170000,0,0,2016-04-18T17:29:59.960000-04:00
1812305,11938c82-3aad-45c4-9ebf-1bf5d2566cb2,1T,THORSEN FRENCH ADVOCACY LLC,400599826,ASTRAZENECA PHARMACEUTICALS LP,2016,first_quarter,PHA,Issues related to access to pharmaceuticals.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,1,2016-04-18T17:44:19.790000-04:00
1812398,ff27060c-1b30-4659-9fb0-badb1a2db81a,Q1,THORSEN FRENCH ADVOCACY LLC,400599826,HEALTHCARE DISTRIBUTION ALLIANCE,2016,first_quarter,PHA,"General issues related to prescription drug abuse.
Issues related to pharmaceutical market value. 
S.483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015.
H.R.471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015.
S. 524: Comprehensive Addiction and Recovery Act of 2015.
H.R. 953: Comprehensive Addiction and Recovery Act of 2015.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2016-04-18T18:01:05.823000-04:00
1812428,599142e9-832a-48af-b36a-c7be41c8b2de,Q1,THORSEN FRENCH ADVOCACY LLC,400599826,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2016,first_quarter,PHA,Issues related to pharmaceutical market value.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-04-18T18:06:37.980000-04:00
1812463,e5ffe25e-d235-4283-844d-bbce90b502a4,Q1,"GILEAD SCIENCES, INC.",287177,GILEAD SCIENCES INC,2016,first_quarter,PHA,"Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; Issues related to coverage and reimbursement of pharmaceuticals; Issues related to Medicare, Medicaid and Affordable Care Act implementation; and FDA issues and 340B.","Commerce, Dept of (DOC),Defense, Dept of (DOD),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Veterans Affairs, Dept of (VA)",,980000,0,0,2016-04-18T18:12:02-04:00
1812656,ba06b247-127f-4448-af16-4ce268db662e,Q1,CAPVIEW ASSOCIATES LLC (DBA CAPVIEW STRATEGIES),401103546,PFIZER INC.,2016,first_quarter,PHA,Issues related to the value of pharmaceuticals including developing sustainable models that support innovation.,"Centers For Medicare and Medicaid Services (CMS),Medicare Payment Advisory Commission (MedPAC)",50000,,0,0,2016-04-18T21:15:30.247000-04:00
1812678,f10308fc-be8a-4102-b1bb-95603e21560b,Q1,WEST FRONT STRATEGIES LLC,401103493,WALGREEN CO.,2016,first_quarter,PHA,"Pharmacy and Medically Underserved Areas Enhancement Act (S. 314 and HR 592), to amend Title IIX of the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved areas;
Comprehensive Addiction and Recovery Act of 2016 (S. 524).","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-04-18T21:30:45.547000-04:00
1812889,d7f26584-6777-440b-a045-18e088c46637,Q1,WINNING STRATEGIES WASHINGTON,50796,KALEO,2016,first_quarter,PHA,"Pharmaceutical drug development, Reducing opiod overdose deaths and S. 707","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-04-19T01:00:48.360000-04:00
1813282,95ad7956-fedf-4b09-a2e8-838f6f2a8155,Q1,THE D MAJOR GROUP,401103162,CVS CAREMARK,2016,first_quarter,PHA,"Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act. Also monitor matters related to H.R. 244, The MAC Transparency Act.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2016-04-19T09:01:12.140000-04:00
1813576,dbfa468c-a729-46f9-b440-fae4080956e7,Q1,GREATER NEW YORK HOSPITAL ASSOCIATION,16830,GREATER NEW YORK HOSPITAL ASSOCIATION,2016,first_quarter,PHA,"Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price ""gag clauses""; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases and support draft reform legislation; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; support reforming the durable medical equipment competitive bidding program; supporting ""any willing pharmacy"" legislation; promoting access to biosimilars (labeling/interchangeability); 21st Century Cures Act (H.R.6) - general support for overall bill, support final pharmacy lock-in policy, oppose PPSA weakening of existing requirements, oppose Section 4004 treatment of infusion drugs furnished through durable medical equipment; Ensuring Seniors Access to Local Pharmacies Act (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Empowerment Act (S.776) - support; Strengthening Medicare Advantage Through Innovation and Transparency for Seniors - oppose; FDA-2014-D-1524-0002 - comments, Administration and Capitol Hill meetings on draft guidance on repackaging of certain human drug products by pharmacies and outsourcing facilities; FDA-2014-N-1459 - comments and Capitol Hill meetings on draft MOU addressing certain distributions of compounded human drug products between states and the FDA; proposed changes to the 340B prescription drug program - oppose; 21st Century Cures Act (H.R.6) - support; proposed amendments to 340b program (not ultimately included in H.R.6) - oppose; provide comments on proposed 340b omnibus guidance (RIN 0906 AB08); Stopping Medication Abuse and Protecting Seniors Act of 2015 (S.1913)- support  (with some concerns about pharmacy lock-in policy); submitted comments on Management Standards for Hazardous Waste Pharmaceuticals (EPA-HQ-RCRA-2007-0932); meeting with DEA on Controlled Substances Act (21 USC 802); proposed changes to regulation of Laboratory Developed Tests (FDA-2011-D-0360-Draft Guidance for Industry, Food and Drug Administration Staff and Clinical Laboratories: Framework for Regulatory Oversight of Laboratory Developed Tests) - oppose.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office",,320000,0,0,2016-04-19T10:13:37.070000-04:00
1813611,5ae8833e-45de-42f9-9eea-de2231859864,Q1,FOOD MARKETPLACE INC.,15097,FOOD MARKETPLACE INC,2016,first_quarter,PHA,"H.R. 1270 / S. 620 - Restore Access to Medication Act
H.R. 592 / S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act

H.R. 2029 - Consolidated Appropriations Act, House Amendments 1 and 2  to Senate Amendment published as Rules Committee Prints 114-39 and 114-40
H.R.3762 - Restoring Americans' Healthcare Freedom Reconciliation Act of 2015

H.R. 793/S. 1190 - the Ensuring Seniors Access to Local Pharmacies Act

Health Savings Act of 2016 - H.R.4469/S.2499","HOUSE OF REPRESENTATIVES,SENATE",,140000,0,0,2016-04-19T10:19:03.710000-04:00
1813818,0c037a8d-ae12-4b3d-a940-e15632243966,Q1,"ARNALL GOLDEN GREGORY, LLP",400713137,PHARMA AND BIOPHARMA OUTSOURCING ASSOCIATION,2016,first_quarter,PHA,FDA issues; Generic Drug Free User Act issues; small business relief legislation,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2016-04-19T10:40:36.057000-04:00
1813926,d62b4867-2bf3-4090-b010-c1a21f98826b,Q1,"MEHLMAN CONSULTING, INC.",284950,WALMART INC,2016,first_quarter,PHA,Implementation of Medicare Part D and the Affordable Care Act.,"HOUSE OF REPRESENTATIVES,SENATE",90000,,0,0,2016-04-19T10:51:51.480000-04:00
1814000,12e47cb8-dd30-4d93-b94d-b784fdcaf5a0,Q1,DENTONS US LLP,36105,PURDUE PHARMA,2016,first_quarter,PHA,U.S. and Canadian regulatory policies regarding prescription drug abuse,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2016-04-19T11:00:55.653000-04:00
1814390,b4ab0eb7-9d20-46ac-a33e-9ba5a57a2892,Q1,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2016,first_quarter,PHA,"Reimbursement of pharmacist services - HR592/S314
Transitions of care
Risk evaluation and mitigation services
Track and trace/supply chain
Health information technology
Immunizations
Compounding
Tele-medicine
Quality rating
AMP FULs/MAC pricing
Biosimiliars
Drug importation
Generics labeling
Pharmacy Benefit Managers
Preferred pharmacy network - HR793
Electronic labeling
21st century cures - HR6
Drug Disposal/Management
Drug Prices","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,30000,0,0,2016-04-19T11:51:51.910000-04:00
1814681,a3d2e4ba-5be7-49d5-a124-c9f302dd3a2c,Q1,WALTER CONSULTING,301697,AMERISOURCEBERGEN CORPORATION,2016,first_quarter,PHA,"H.R. 471, the Ensuring Patient Access and Effective Drug Enforcement Act of 2015
S.483, The Regulatory Transparency, Patient Access and Effective Drug Enforcement Act","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-04-19T12:23:09.600000-04:00
1814683,de85661c-f0a1-491b-aaed-a1817c6da719,Q1,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2016,first_quarter,PHA,"H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas.
H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas.
S.524 Comprehensive Addiction and Recovery Act of 2015. IPC is against as currently written.","HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2016-04-19T12:23:11.037000-04:00
1814841,13c4c552-3c07-422d-ae60-9267db8d9505,Q1,JOHNS HOPKINS UNIVERSITY,20664,JOHNS HOPKINS UNIVERSITY,2016,first_quarter,PHA,Pharmaceutical drug price increases; 340B drug discount program,"Centers For Medicare and Medicaid Services (CMS),Defense Advanced Research Projects Agency (DARPA),Energy, Dept of,HOUSE OF REPRESENTATIVES,SENATE",,110000,0,0,2016-04-19T12:36:10.383000-04:00
1815154,b7139681-1588-4b4c-8121-cd4cf273e326,Q1,FOLEY & LARDNER LLP,15042,PAR PHARMACEUTICAL,2016,first_quarter,PHA,FDA issues,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2016-04-19T13:14:13.327000-04:00
1815476,915a2330-549e-47e3-955f-1d2d4fda58d7,Q1,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2016,first_quarter,PHA,"Increased appropriations for systems to shorten the time between development of a drug and its release to the public
FDA reform as it relates to drug development and research         
Collaborative research on drug development                                
Human factors research related to neuropharmaceuticals","Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)",,86662,0,0,2016-04-19T13:47:17.157000-04:00
1815613,f760cf86-870f-44f4-8ed0-f0d9492016b5,Q1,CHAMBER HILL STRATEGIES,400645947,AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL),2016,first_quarter,PHA,"Implementation issues related to P.L. 113-54, the Drug Quality and Security Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2016-04-19T14:02:54.800000-04:00
1816356,0a29e83e-4b1c-47c9-b8ec-74419f54331d,Q1,HANCE SCARBOROUGH,17443,ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS,2016,first_quarter,PHA,"Federal legislation affecting the practice of pharmacy, and FDA and DEA regulations of compounded drugs.","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2016-04-19T15:10:42.920000-04:00
1816895,eb091650-2fc3-4e6e-8c44-c6569b13268b,Q1,OREGON HEALTH & SCIENCE UNIVERSITY,30291,OREGON HEALTH & SCIENCE UNIVERSITY,2016,first_quarter,PHA,340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance.,"HOUSE OF REPRESENTATIVES,SENATE",,70000,0,0,2016-04-19T15:52:32.423000-04:00
1816992,3929b5cb-a5b2-4b0d-af64-400acaabf0b7,Q1,UNIVERSITY OF PITTSBURGH MEDICAL CENTER,32065,UNIVERSITY OF PITTSBURGH MEDICAL CENTER,2016,first_quarter,PHA,Urge Congress to oppose cuts to the 340B program and address the escalation in drug prices.,"HOUSE OF REPRESENTATIVES,SENATE",,260000,0,0,2016-04-19T15:59:40.643000-04:00
1817061,9563d79e-4cad-42a2-9d3c-9d7d2c24f6df,Q1,COVINGTON & BURLING LLP,11195,"FABRE-KRAMER PHARMACEUTICALS, INC",2016,first_quarter,PHA,Policy regarding demonstration of effectiveness for new drug approvals.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2016-04-19T16:06:40.910000-04:00
1817074,889ff66a-ab5f-4a99-8473-618ae8f0fd8e,Q1,ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA MNK PHARMACEUTICALS),401095056,ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA,2016,first_quarter,PHA,"Highly enriched to Low enriched uranium (HEU-LEU) related issues for Nuclear Medicine (no specific bill number); 21st Century CURES Act (H.R.6)Issues related to ""real world"" clinical evidence; Issues related to Opioid abuse and alternatives to opioids (no specific bill number).","Energy, Dept of,HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE",,590000,0,0,2016-04-19T16:06:44-04:00
1817115,dafc1fa7-2df4-43ca-9ae1-f128b8364e2a,Q1,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2016,first_quarter,PHA,"Importation of prescription drugs (S. 122, H.R. 2228)
Rx Pedigree (PL 113-54)
Prescription Drug Monitoring Programs (S. 480, H.R. 1725) 
Prescription Drug Abuse - General issues related to Rx drug abuse (H.R. 471, S. 483, S. 524, H.R. 953)
21st Century Cures (H.R. 6)","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2016-04-19T16:10:13.207000-04:00
1817321,56c22f7d-2f35-4dbf-ac85-a343bb3da92e,Q1,AMERICAN ACADEMY OF FAMILY PHYSICIANS,1342,AMERICAN ACADEMY OF FAMILY PHYSICIANS,2016,first_quarter,PHA,"S 524/HR 953 - Comprehensive Addiction and Recovery Act: Supporting drug monitoring programs & interstate exchange of data, and opposing mandatory professional education for prescribing physicians. 
No Bill No.-Prescription Drug Abuse: Supporting drug monitoring programs and interstate exchange of data.","Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),SENATE,White House Office",,715182,0,0,2016-04-19T16:34:48.367000-04:00